Clinical Trial Update: Study of Efficacy and Safety of Grazoprevir (MK-5172)/Elbasvir (MK-8742) Combination Regimen for Treatment-Naïve Participants With Chronic Hepatitis C Virus Genotypes 1, 4, and 6 (MK-5172-060) [Phase 3]

View source ↗

Summary

Phase 3 study of grazoprevir/elbasvir in treatment-naïve chronic hepatitis C patients showed completed results with posted outcomes in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Grazoprevir/elbasvir combination regimen

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Chronic Hepatitis C Virus | Phase 3 | Status: COMPLETED | Results posted: 2016-04-12